Clinical Trials
5
Active:0
Completed:2
Trial Phases
2 Phases
Phase 2:1
Not Applicable:3
Drug Approvals
72
TGA:72
Drug Approvals
EPKINLY epcoritamab 48mg/0.8mL solution for injection vial (404977)
- Product Name
- EPKINLY epcoritamab 48mg/0.8mL solution for injection vial
- Approval Date
- Jan 6, 2025
TGA
EPKINLY epcoritamab 4mg/0.8mL concentrate solution for injection vial (404978)
- Product Name
- EPKINLY epcoritamab 4mg/0.8mL concentrate solution for injection vial
- Approval Date
- Jan 6, 2025
TGA
SKYRIZI risankizumab 180 mg/1.2 mL solution for injection pre-filled cartridge with on-body delivery system (427219)
- Product Name
- SKYRIZI risankizumab 180 mg/1.2 mL solution for injection pre-filled cartridge with on-body delivery system
- Approval Date
- Nov 15, 2024
TGA
ALPHAGAN P 1.0 brimonidine tartrate 1 mg/mL eye drop bottle (421114)
- Product Name
- ALPHAGAN P 1.0 brimonidine tartrate 1 mg/mL eye drop bottle
- Approval Date
- Oct 23, 2024
TGA
VYALEV foslevodopa 2400 mg/10 mL and foscarbidopa 120 mg/10 mL solution for subcutaneous infusion vial (372902)
- Product Name
- VYALEV foslevodopa 2400 mg/10 mL and foscarbidopa 120 mg/10 mL solution for subcutaneous infusion vial
- Approval Date
- Mar 27, 2024
TGA
AQUIPTA atogepant 60 mg tablet blister pack (391362)
- Product Name
- AQUIPTA atogepant 60 mg tablet blister pack
- Approval Date
- Dec 12, 2023
TGA
AQUIPTA atogepant 30 mg tablet blister pack (421965)
- Product Name
- AQUIPTA atogepant 30 mg tablet blister pack
- Approval Date
- Dec 12, 2023
TGA
AQUIPTA atogepant 10 mg tablet blister pack (391361)
- Product Name
- AQUIPTA atogepant 10 mg tablet blister pack
- Approval Date
- Dec 12, 2023
TGA
SKYRIZI risankizumab 600 mg/10 mL concentrate solution for intravenous infusion vial (375984)
- Product Name
- SKYRIZI risankizumab 600 mg/10 mL concentrate solution for intravenous infusion vial
- Approval Date
- Oct 5, 2022
TGA
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Not Applicable
3 (75.0%)Phase 2
1 (25.0%)No trials found
News
No news found